BR112018075688A2 - anti-c5 antibodies and methods of use - Google Patents
anti-c5 antibodies and methods of useInfo
- Publication number
- BR112018075688A2 BR112018075688A2 BR112018075688-1A BR112018075688A BR112018075688A2 BR 112018075688 A2 BR112018075688 A2 BR 112018075688A2 BR 112018075688 A BR112018075688 A BR 112018075688A BR 112018075688 A2 BR112018075688 A2 BR 112018075688A2
- Authority
- BR
- Brazil
- Prior art keywords
- present
- antibody
- provides
- antibodies
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
a presente invenção fornece anticorpos anti-c5 e métodos de uso dos mesmos. em algumas modalidades, um anticorpo anti-c5 isolado da presente invenção se liga a um epitopo dentro da cadeia beta de c5 com uma afinidade maior em um ph neutro do que em um ph ácido. a invenção também fornece ácidos nucleicos isolados que codificam um anticorpo anti-c5 da presente invenção. a invenção também fornece células hospedeiras que compreendem um ácido nucleico da presente invenção. a invenção também fornece um método de produção de um anticorpo que compreende cultivar uma célula hospedeira da presente invenção tal que o anticorpo seja produzido. a invenção ainda fornece um método de produção de um anticorpo anti-c5 que compreende imunizar um animal contra um polipeptídeo que compreende o domínio mg1-mg2 da cadeia beta de c5. os anticorpos anti-c5 da presente invenção podem ser para uso como um medicamento.The present invention provides anti-C5 antibodies and methods of using them. In some embodiments, an isolated anti-c5 antibody of the present invention binds to an epitope within the c5 beta chain with a higher affinity at a neutral ph than at an acid ph. The invention also provides isolated nucleic acids encoding an anti-c5 antibody of the present invention. The invention also provides host cells comprising a nucleic acid of the present invention. The invention also provides a method of producing an antibody comprising culturing a host cell of the present invention such that the antibody is produced. The invention further provides a method of producing an anti-c5 antibody comprising immunizing an animal against a polypeptide comprising the mg1-mg2 domain of the c5 beta chain. The anti-c5 antibodies of the present invention may be for use as a medicament.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016-120325 | 2016-06-17 | ||
| JP2016120325 | 2016-06-17 | ||
| PCT/JP2017/022253 WO2017217524A1 (en) | 2016-06-17 | 2017-06-16 | Anti-c5 antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018075688A2 true BR112018075688A2 (en) | 2019-04-02 |
Family
ID=59969459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018075688-1A BR112018075688A2 (en) | 2016-06-17 | 2017-06-16 | anti-c5 antibodies and methods of use |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3472316A4 (en) |
| JP (3) | JP6202774B1 (en) |
| KR (2) | KR101852739B1 (en) |
| CN (3) | CN109312326B (en) |
| AU (1) | AU2017285763B2 (en) |
| BR (1) | BR112018075688A2 (en) |
| CA (1) | CA3021956A1 (en) |
| CL (1) | CL2018003573A1 (en) |
| CR (1) | CR20190013A (en) |
| EA (1) | EA201990018A1 (en) |
| IL (2) | IL300611A (en) |
| MX (2) | MX2018015030A (en) |
| MY (1) | MY187848A (en) |
| PE (2) | PE20190394A1 (en) |
| PH (1) | PH12018502354A1 (en) |
| SG (2) | SG10201800265UA (en) |
| TW (4) | TWI807666B (en) |
| UA (1) | UA126561C2 (en) |
| WO (1) | WO2017217524A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4001409A1 (en) | 2006-03-31 | 2022-05-25 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| EP3521311A1 (en) | 2008-04-11 | 2019-08-07 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| CA2819356C (en) | 2010-11-30 | 2023-01-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
| ES2899894T3 (en) | 2014-12-19 | 2022-03-15 | Chugai Pharmaceutical Co Ltd | Anti-C5 antibodies and methods of use |
| WO2017218515A1 (en) | 2016-06-14 | 2017-12-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
| SG10201800265UA (en) * | 2016-06-17 | 2018-02-27 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| CN109689099B (en) | 2016-08-05 | 2023-02-28 | 中外制药株式会社 | Composition for preventing or treating IL-8-related diseases |
| CN111278857A (en) * | 2017-10-04 | 2020-06-12 | 亚力兄制药公司 | Dosage and administration of anti-C5 antibody to treat patients with membranoproliferative glomerulonephritis |
| CA3083113A1 (en) | 2017-12-13 | 2019-06-20 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibody combinations and uses thereof |
| US20220177556A1 (en) * | 2018-09-06 | 2022-06-09 | The Trustees Of The University Of Pennsylvania | Humanized anti-c5 antibodies and uses thereof |
| MX2021012997A (en) * | 2019-04-24 | 2022-03-04 | Univ Pennsylvania | Bi-functional humanized anti-c5 antibodies and factor h fusion proteins and uses thereof. |
| CN113563467A (en) * | 2020-04-28 | 2021-10-29 | 上海普铭生物科技有限公司 | Antibodies against human complement protein C5 and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0230985Y2 (en) | 1985-07-08 | 1990-08-21 | ||
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| ATE495618T1 (en) | 2001-06-12 | 2011-01-15 | Ericsson Telefon Ab L M | SYNCHRONIZATION IN A TERRESTRIAL UMTS RADIO ACCESS NETWORK (UTRAN) |
| BRPI0211953B8 (en) | 2001-08-17 | 2021-05-25 | Genentech Inc | monoclonal antibody or antigen-binding fragment that binds to c5 and c5a without the prevention of c5b formation, cell lineage, pharmaceutical composition, as well as in vitro method to inhibit c5a activity and in vitro diagnostic method |
| JP4333939B2 (en) | 2001-08-27 | 2009-09-16 | ロード・コーポレーション | Trolley wire suspension system |
| DE10253331A1 (en) | 2002-11-14 | 2004-06-03 | Symrise Gmbh & Co. Kg | Use of trans-pellitori as a flavoring |
| US7267849B2 (en) | 2004-03-02 | 2007-09-11 | Nitto Denko Corporation | Compensator for liquid crystal display |
| KR20080069889A (en) | 2007-03-20 | 2008-07-29 | (주)화도 | Pe pipe |
| KR20100015773A (en) * | 2007-03-22 | 2010-02-12 | 노파르티스 아게 | C5 antigens and uses thereof |
| JP5336846B2 (en) | 2007-04-11 | 2013-11-06 | 積水化学工業株式会社 | Method for producing crosslinked polyvinyl acetal resin and crosslinked polyvinyl acetal resin |
| EP3521311A1 (en) * | 2008-04-11 | 2019-08-07 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| MY159396A (en) * | 2008-08-05 | 2016-12-30 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c5 |
| KR20100054403A (en) | 2008-11-14 | 2010-05-25 | 삼성전자주식회사 | Online composition apparatus and method for writing by multiple participants |
| BR112012022917A2 (en) * | 2010-03-11 | 2017-01-10 | Pfizer | ph-dependent antigen binding antibodies |
| TW201206466A (en) * | 2010-03-11 | 2012-02-16 | Rinat Neuroscience Corp | Antibodies with pH dependent antigen binding |
| KR20110111007A (en) | 2010-04-02 | 2011-10-10 | 이화여자대학교 산학협력단 | Octahydro-binaphthol derivatives for l/d optical conversion and optical resolution |
| KR20110122011A (en) | 2010-05-03 | 2011-11-09 | 황보철종 | System for administrating combine store point and method therefor |
| KR20150041662A (en) * | 2012-08-13 | 2015-04-16 | 리제너론 파아마슈티컬스, 인크. | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| BR112015018438A2 (en) * | 2013-01-31 | 2017-07-18 | Seoul Nat Univ R&Db Foundation | c5 antibody and method for preventing and treating complement-related diseases |
| EP3473272A1 (en) * | 2013-03-29 | 2019-04-24 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| ES2899894T3 (en) * | 2014-12-19 | 2022-03-15 | Chugai Pharmaceutical Co Ltd | Anti-C5 antibodies and methods of use |
| RU2742606C2 (en) * | 2015-12-18 | 2021-02-09 | Чугаи Сейяку Кабусики Кайся | C5 antibodies and methods for using them |
| SG10201800265UA (en) * | 2016-06-17 | 2018-02-27 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
-
2017
- 2017-06-16 SG SG10201800265UA patent/SG10201800265UA/en unknown
- 2017-06-16 EA EA201990018A patent/EA201990018A1/en unknown
- 2017-06-16 AU AU2017285763A patent/AU2017285763B2/en active Active
- 2017-06-16 CN CN201780036916.4A patent/CN109312326B/en active Active
- 2017-06-16 TW TW111107923A patent/TWI807666B/en active
- 2017-06-16 JP JP2017118226A patent/JP6202774B1/en active Active
- 2017-06-16 IL IL300611A patent/IL300611A/en unknown
- 2017-06-16 CN CN202211018018.5A patent/CN115960223A/en active Pending
- 2017-06-16 PE PE2018003148A patent/PE20190394A1/en unknown
- 2017-06-16 CN CN202211023851.9A patent/CN115925922A/en active Pending
- 2017-06-16 TW TW106120143A patent/TWI610941B/en active
- 2017-06-16 CA CA3021956A patent/CA3021956A1/en active Pending
- 2017-06-16 KR KR1020177020545A patent/KR101852739B1/en active IP Right Grant
- 2017-06-16 WO PCT/JP2017/022253 patent/WO2017217524A1/en active Application Filing
- 2017-06-16 TW TW112120479A patent/TW202337903A/en unknown
- 2017-06-16 TW TW106141573A patent/TWI789369B/en active
- 2017-06-16 KR KR1020187010179A patent/KR102226975B1/en active IP Right Grant
- 2017-06-16 EP EP17813418.5A patent/EP3472316A4/en active Pending
- 2017-06-16 MY MYPI2018002581A patent/MY187848A/en unknown
- 2017-06-16 UA UAA201810992A patent/UA126561C2/en unknown
- 2017-06-16 BR BR112018075688-1A patent/BR112018075688A2/en unknown
- 2017-06-16 SG SG11201705584VA patent/SG11201705584VA/en unknown
- 2017-06-16 CR CR20190013A patent/CR20190013A/en unknown
- 2017-06-16 MX MX2018015030A patent/MX2018015030A/en unknown
- 2017-06-16 PE PE2023002969A patent/PE20240825A1/en unknown
- 2017-08-28 JP JP2017162934A patent/JP7032077B2/en active Active
-
2018
- 2018-11-08 PH PH12018502354A patent/PH12018502354A1/en unknown
- 2018-12-04 MX MX2023001360A patent/MX2023001360A/en unknown
- 2018-12-12 IL IL263657A patent/IL263657A/en unknown
- 2018-12-12 CL CL2018003573A patent/CL2018003573A1/en unknown
-
2022
- 2022-02-24 JP JP2022026406A patent/JP2022091748A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018075688A2 (en) | anti-c5 antibodies and methods of use | |
| BR112018009067A8 (en) | anti-c5 antibodies and methods of use | |
| BR112017011235A2 (en) | anti-c5 antibodies and methods of use | |
| AR103161A1 (en) | ANTIMIOSTATINE ANTIBODIES AND VARIANTS FC REGIONS AS WELL AS METHODS OF USE | |
| BR112015023262A2 (en) | isolated antibody, isolated nucleic acid, host cell, method for producing an antibody, immunoconjugate, pharmaceutical formulation and uses of the antibody | |
| AR113342A1 (en) | CD47 / PD-L1 SPECIFIC ANTIBODIES | |
| BR112015019603A2 (en) | ISOLATED NUCLEIC ACID MOLECULES, ISOLATED POLYPEPTIDE MOLECULES, ISOLATED CAR MOLECULES, ANTI-EGFRVIII BINDING DOMAIN, VECTOR, CELL AND USE OF AN EFFECTIVE AMOUNT THEREOF, AND METHODS FOR PRODUCING A CELL AND PRODUCING A POPULATION OF CELLS MODIFIED BY RNA | |
| CL2019001193A1 (en) | Lag-3 binding molecules and methods of using them. (divisional application 201703132). | |
| CL2018003136A1 (en) | Specific binding proteins and uses thereof. | |
| BR112017018770A2 (en) | reduced immune tolerance induced by pd-l1 | |
| BR112016014293A2 (en) | canine crystallizable fragment region, antibody, nucleic acid, expression vector, host cell, pharmaceutical composition, and method for enhancing the activity of an immune cell | |
| BR112016013347A8 (en) | anti-il-33 neutralizing human monoclonal antibody, pharmaceutical composition, cytokine expression inhibitor, epitope, nucleic acid molecule, vector, host cell, method of production and use thereof. | |
| BR112012023010A8 (en) | ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF THE SAME THAT SPECIFICALLY BINDS TO CD37, IMMUNOCONJUGATE COMPRISING THE SAME, USE OF THE SAID ANTIBODY, FRAGMENT AND IMMUNOCONJUGATE, COMPOSITION COMPRISING THE SAME, KIT, ISOLATED CELL, AS WELL AS IN VITRO METHOD TO INHIBIT GROWTH MENT OF A CELL THAT EXPRESSES CD37 | |
| BR112015019341A2 (en) | ANTI-TNF-ALPHA ANTIBODY, COMPOSITION COMPRISING THE ANTIBODY, METHOD FOR PRODUCING A POPULATION OF ANTIBODIES, MAMMARY GLAND EPITHELIAL CELLS, TRANSGENIC NON-HUMAN MAMMAL, AND, MONOCLONAL ANTI-TNF ANTIBODY COMPOSITION | |
| BR112015019343A2 (en) | ANTI-HER2 ANTIBODY, COMPOSITION, METHOD FOR PRODUCING A POPULATION OF ANTIBODIES, MAMMARY GLAND EPITHELIAL CELLS, AND, TRANSGENIC NON-HUMAN MAMMAL | |
| BR112022000628A2 (en) | Anti-Tigit antibodies and their application | |
| BR112018010669A2 (en) | Anti-PCSK9 antibody and its application | |
| AR115695A1 (en) | MULTIFUNCTIONAL PROTEIN MOLECULES INCLUDING DECORINE AND THE USE OF THEM | |
| BR112015027388A2 (en) | MONOCLONAL ANTIBODY OR PORTION THEREOF THAT BIDS TO CXCR5, ITS PRODUCTION METHOD AND ITS USE, POLYNUCLOTIDES, EXPRESSION VECTORS, HOST CELL, AND PHARMACEUTICAL COMPOSITION | |
| BR112018005464A2 (en) | fc-containing protein expression | |
| BR112021022742A2 (en) | Method of expressing antigen-binding proteins in the nervous system and use of an expression construct | |
| BR112023021587A2 (en) | ANTI-TSLP FAB WITH IMPROVED STABILITY, KIT, COMPOSITION, VECTOR, CELL, PRODUCTION METHOD AND USES | |
| BR112016003441A2 (en) | isolated antibody or antigen binding fragment thereof, drug-to-antibody conjugate, methods for eliminating cells expressing low levels of prlr and a class i cytokine receptor and for inhibiting or attenuating tumor growth, and, pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023000238-5 PROTOCOLO 870230001345 EM 05/01/2023 16:22. |